P A Marks
Impact in
- Molecular Biology top 0.5%
- Histone Deacetylase Inhibitors Research
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Ubiquitin and proteasome pathways
- RNA modifications and cancer
- Oncology top 1%
- Peptidase Inhibition and Analysis
Papers in
-
- Histone Deacetylase Inhibitors Research 11
- RNA modifications and cancer 10
- Protein Degradation and Inhibitors 7
- RNA and protein synthesis mechanisms 7
- DNA and Nucleic Acid Chemistry 7
- Epigenetics and DNA Methylation 4
- Physiology 15
- Erythrocyte Function and Pathophysiology 13
- Co-authors
- Richard A. Rifkind (22 shared papers)Victoria M. Richon (9 shared papers)Raphael B. Parmigiani (1 shared paper)Weisheng Xu (1 shared paper)Lang Ngo (6 shared papers)R A Rifkind (8 shared papers)Weili Xu (2 shared papers)A Bank (11 shared papers)
- Journals
- Proceedings of the National Academy of Sciences (21 papers)Journal of Biological Chemistry (6 papers)Journal of Clinical Investigation (3 papers)Oncogene (2 papers)Cold Spring Harbor Symposia on Quantitative Biology (2 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
P A Marks
65 papers receiving 8.3k citations
P A Marks's Hit Papers
Peers
Comparison fields: 5 of 129
- Molecular Biology 6.9k
- Oncology 1.6k
- Hematology 669
- Genetics 610
- Physiology 181
Countries citing papers authored by P A Marks
This map shows the geographic impact of P A Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P A Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P A Marks more than expected).
Fields of papers citing papers by P A Marks
This network shows the impact of papers produced by P A Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P A Marks. The network helps show where P A Marks may publish in the future.
Co-authors
The 25 scholars most cited alongside P A Marks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 66 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Histone deacetylase inhibitors: molecular mechanisms of action Hit paper breakdown → | 2007 | 1255 |
| 2 | Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells Hit paper breakdown → | 2000 | 1013 |
| 3 | Erythroleukemic Differentiation Hit paper breakdown → | 1978 | 618 |
| 4 | Histone deacetylase inhibitors: Potential in cancer therapy Hit paper breakdown → | 2009 | 591 |
| 5 | Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Hit paper breakdown → | 2000 | 521 |
| 6 | Discovery and development of SAHA as an anticancer agent Hit paper breakdown → | 2007 | 517 |
| 7 | 2004 | 473 | |
| 8 | 2005 | 416 | |
| 9 | 1996 | 348 | |
| 10 | 2003 | 297 | |
| 11 | 1977 | 214 | |
| 12 | 1986 | 179 | |
| 13 | Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. | 1999 | 154 |
| 14 | 1972 | 140 | |
| 15 | The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. | 2001 | 129 |
| 16 | 1977 | 113 | |
| 17 | Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. | 2001 | 105 |
| 18 | 1973 | 95 | |
| 19 | 1975 | 89 | |
| 20 | 1972 | 84 |
About P A Marks
P A Marks is a scholar working on Molecular Biology, Physiology, Genetics, Oncology and Rheumatology, having authored 66 papers that have together received 8.8k indexed citations. Recurring topics across this work include Erythrocyte Function and Pathophysiology (13 papers), Hemoglobinopathies and Related Disorders (11 papers), Histone Deacetylase Inhibitors Research (11 papers), RNA modifications and cancer (10 papers), Protein Degradation and Inhibitors (7 papers), RNA and protein synthesis mechanisms (7 papers), DNA and Nucleic Acid Chemistry (7 papers) and Epigenetics and DNA Methylation (4 papers). The work is most often cited by research in Molecular Biology (6.9k citations), Oncology (1.6k citations), Hematology (669 citations), Genetics (610 citations) and Physiology (181 citations). P A Marks has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Richard A. Rifkind, Victoria M. Richon, Raphael B. Parmigiani, Weisheng Xu, Lang Ngo, R A Rifkind, Weili Xu, A Bank, C. Gui and M Terada. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry, Journal of Clinical Investigation, Oncogene and Cold Spring Harbor Symposia on Quantitative Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.